首页> 外文期刊>Frontiers in Molecular Biosciences >DNA Damage in Healthy Individuals and Respiratory Patients after Treating Whole Blood In vitro with the Bulk and Nano Forms of NSAIDs
【24h】

DNA Damage in Healthy Individuals and Respiratory Patients after Treating Whole Blood In vitro with the Bulk and Nano Forms of NSAIDs

机译:散装和纳米形式的NSAID体外处理全血后健康个体和呼吸道患者的DNA损伤

获取原文
           

摘要

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX enzyme activity which affects the inflammatory response. Inflammation is associated with increasing cancer incidence. Pre-clinical and clinical studies have shown that NSAID treatment could cause an anti-tumour effect in cancers. In the present study, blood was taken from healthy individuals (n=17) and patients with respiratory diseases or lung cancer (n=36). White blood cells (WBC) were treated with either a micro-suspension, i.e. bulk (B) or nano-suspension (N) of aspirin (ASP) or ibuprofen (IBU) up to 500 μg/ml in the comet assay and up to 125 μg/ml in the micronucleus assay. In this study results were compared against untreated lymphocytes and their corresponding treated groups. The results showed, thgat NSAIDs in their nano form significantly reduced the DNA damage in WBCs from lung cancer patients in bulk and nano compared to untreated lymphocytes. Also, there was a decrease in the level of DNA damage in the comet assay after treating WBCs from healthy individuals, asthma and COPD groups with aspirin N (ASP N) but not with IBU N. In addition, the number of micronuclei decreased after treatment with NSAIDs in their nano form (ASP N and IBU N) in the healthy as well as in the lung cancer group. However, this was not the case for micronucleus frequency in asthma and COPD patients. These data show that lymphocytes from different groups respond differently to treatment with ASP and IBU as measured by comet assay and micronucleus assay, and that the size of the suspended particles of the drugs affects responses.
机译:非甾体类抗炎药(NSAIDs)会抑制COX酶的活性,从而影响炎症反应。炎症与癌症发病率增加有关。临床前和临床研究表明,NSAID治疗可引起癌症的抗肿瘤作用。在本研究中,血液采自健康个体(n = 17)和患有呼吸系统疾病或肺癌(n = 36)的患者。用微悬浮液(即散装(B)或纳米悬浮液)的阿司匹林(ASP)或布洛芬(IBU)对白细胞(WBC)进行了彗星分析,其浓度最高可达500μg/ ml。在微核分析中为125μg/ ml。在这项研究中,将结果与未处理的淋巴细胞及其相应的治疗组进行了比较。结果表明,与未经处理的淋巴细胞相比,以纳米形式存在的喉头NSAIDs可以显着减少散发和纳米形态的肺癌患者的WBC中的DNA损伤。同样,用阿司匹林N(ASP N)治疗健康个体,哮喘和COPD组的白细胞后,彗星试验中的DNA损伤水平降低,而IBU N则没有。此外,治疗后微核数量减少了在健康人群和肺癌人群中使用纳米形式的NSAID(ASP N和IBU N)。但是,哮喘和COPD患者的微核频率并非如此。这些数据表明,通过彗星试验和微核试验测量,来自不同组的淋巴细胞对ASP和IBU的治疗反应不同,并且药物悬浮颗粒的大小会影响反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号